Amadeus V Technology Fund has closed with $153m in funding, having already backed multiple spinouts.
Amadeus Capital Partners, a UK-based venture capital firm, today closed its latest fund at £110m ($153m) from limited partners including cornerstone investor British Patient Capital.
Amadeus V Technology Fund focuses on seed and series A-stage deeptech startups across five core areas: artificial intelligence and machine learning; autonomous systems and human-computer interfaces; enterprise software-as-a-service and cybersecurity; digital health and medtech; and novel materials and quantum technologies.
The fund has already invested in four companies, including Ori Biotech, a cell and gene therapy production spinout of University College London; Xampla, a producer of plant protein-derived materials spun out of University of Cambridge; and Riverlane, a quantum software developer also spun out of Cambridge.
The fourth company is XYZ Reality, a developer of augmented reality technology for the construction industry that is also backed by construction firm J Coffey Construction, according to our sister site Global Corporate Venturing.
